R.FosterW
Non-approved Therapies for Obesity Incretin-based Treatments Since the isolation of the peptide exendin-4 from Heloderma suspectum (Gila Monster) lizard venom in 1992 [25], several drugs that manipulate the incretin axis have been produced and approved for use in people with T2D including exenatide (2005), liraglutide (2009), lixisenatide (2013), albiglutide (2014, withdrawn 2017), dulaglutide (2014) and semaglutide (2017) [26]
Deficiencies in vitamin B12 can cause fatigue, weakness, and nerve issues
Another study showed that 18% of people gained 100% or more of their weight back after 12 months
Stefanski, Tirzepatide Once Weekly for the Treatment of Obesity
Twelve studies included individuals with OCD [39,40,41, 43,44,45,46,47, 50, 51, 53, 55], four others included individuals with trichotillomania [42, 48, 52, 54], and the remaining study included individuals with excoriation disorder [49]